Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.
December 22, 2021
Share
Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million on December 23, 2021. Getinge has paid SEK 596 million for 100% of the equity interest in Talis Clinical LLC on a debt-free basis and subject to customary working capital adjustments. In addition, additional earn-outs may be paid up until 2026 to the extent that the agreed milestone for each earn-out is reached. The purchase price is financed with available cash previously raised in the Swedish Debt Capital Market. Getinge does not expect any material integration costs and the acquisition is not expected to have a material impact on Getinge's earnings in the near term. Russell Hilton, Tyler Pate, Alex Hecht, David Teske, Maki DePalo, Sara Guercio, Brett Coburn and Kaitlin Owen, Blake MacKay of Alston & Bird LLP acted as legal advisors to Getinge. KPMG acted as the Investment Advisor to Talis Clinical.
Getinge AB (OM:GETI B) completed the acquisition of Talis Clinical, LLC on December 23, 2021.
Getinge AB is the world's leader in producing and marketing medical equipment intended to health care facilities (clinics, hospitals, rest homes, etc.). Net sales break down by family of products as follows:
- medical systems (57.4%): equipment for operating rooms (primarily tables and lighting systems), ventilators and heart and lung machines, etc.;
- hospital sterilization equipment (29.4%);
- contamination prevention equipment (13.2%): in the fields of biopharmaceutical production, biomedical research, manufacturing of medical devices and laboratory applications.
Net sales break down by source of income into sales of equipment (45.3%), consumables (37.1%), services and spare parts (17.6%).
At the end of 2021, the group had 20 production sites worldwide.
Net sales are distributed geographically as follows: Sweden (1.8%), Europe/Middle East/Africa (35.8%), Americas (37.9%) and Asia/Pacific (24.5%).
GETINGE AB 
